Pacira BioSciences (PCRX) – Major News
-
Pacira Pharma (PCRX) Misses Q4 EPS by 34c, provides guidance
-
Pacira Pharma (PCRX) Misses Q3 EPS by 6c
-
Pacira Pharma (PCRX) Misses Q1 EPS by 104c
-
Pacira Pharma (PCRX) Misses Q4 EPS by 3c
-
Pacira Pharma (PCRX) Misses Q3 EPS by 83c
-
Pacira Pharma (PCRX) Misses Q2 EPS by 35c
-
Pacira Pharma (PCRX) Misses Q1 EPS by 19c
-
Pacira Pharma (PCRX) Tops Q4 EPS by 9c
-
Pacira Pharma (PCRX) Tops Q3 EPS by 7c
-
Pacira BioSciences (PCRX) Confirms Deal to Acquire Flexion Therapeutics (FLXN)
-
Pacira Pharma (PCRX) Tops Q2 EPS by 8c
-
Pacira Pharma (PCRX) Misses Q1 EPS by 7c
-
Pacira Pharma (PCRX) Tops Q4 EPS by 8c
-
Pacira Pharma (PCRX) Tops Q3 EPS by 7c, Revenues Beat
-
Pacira Pharma (PCRX) Tops Q2 EPS by 3c, Revenues Beat
-
Pacira Pharma (PCRX) Tops Q1 EPS by 22c, Revenues Beat
-
Pacira Pharma (PCRX) Tops Q4 EPS by 12c, Revenue Beats; Offers FY20 Revenue Guidance
-
Pacira Pharma (PCRX) Tops Q3 EPS by 15c
-
Pacira Pharma (PCRX) Tops Q2 EPS by 6c, Revenues Beat; Provides FY19 Sales Outlook
-
Pacira Pharma (PCRX) Misses Q1 EPS by 4c
-
Pacira Pharma (PCRX) Tops Q4 EPS by 19c
-
UPDATE: Pacira Pharma (PCRX) Tops Q3 EPS by 23c, Revenues Beat; Boosts FY18 Revenue Outlook
-
Pacira Pharma (PCRX) Tops Q2 EPS by 17c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus
-
Pacira Pharma (PCRX) Reports In-Line Q1 EPS
-
Pacira Pharma (PCRX) Tops Q4 EPS by 28c
-
Pacira Pharma (PCRX) Doesn't Win FDA Panel Backing of EXPAREL in 6 to 4 Vote Against Approval
-
Pacira Pharma (PCRX) Tops Q3 EPS by 17c, Miss on Revenues
-
Pacira Pharma (PCRX) Misses Q2 EPS by 8c
-
Pacira Pharma (PCRX) Misses Q1 EPS by 15c
-
Pacira Pharma (PCRX) Tops Q4 EPS by 8c
-
Pacira Pharma (PCRX) Reports Preliminary 2016 Revenues of $276.4M, Q4 Sales of $72.9M
-
Pacira Pharma (PCRX) Tops Q3 Views
-
Pacira Pharma (PCRX) Tops Q2 EPS by 16c
-
Pacira Pharma (PCRX) Tops Q1 EPS by 8c; EXPAREL Sales Rose 14%
-
Pacira Pharma (PCRX) Misses Q4 EPS by 5c, Sales Beat
-
Pacira Pharma (PCRX) Tops Q3 EPS by 20c
-
Pacira Pharma (PCRX) Misses Q2 EPS by 1c
-
Pacira Pharma (PCRX) Tops Q2 EPS by 7c
-
Pacira Pharma (PCRX) Tops Q4 EPS by 8c
-
Pacira Pharma (PCRX) Tops Q3 EPS by 4c
-
Pacira Pharmaceuticals (PCRX) Tops Q2 EPS by 25c
-
Pacira Pharmaceuticals (PCRX) Posts Q1 Loss of 19c/Share
-
Pacira Pharmaceuticals (PCRX) Posts Q3 Loss of 30c/Share
-
Pacira Pharma (PCRX) EXPAREL Phase 3 Missed Primary Endpoint
-
Pacira Pharmaceuticals (PCRX) Posts Q4 Loss of 50c/Share
-
Pacira Pharmaceuticals (PCRX) Posts Q3 Loss of 49c/Share
-
Pacira Pharmaceuticals (PCRX) Posts Q2 Loss of 27c/Share
-
Pacira Pharmaceuticals (PCRX) Posts Q4 Loss of 72c/Share
-
Pacira Pharmaceuticals (PCRX) Posts Narrower than Expected Q3 Loss; Guides FY11 Revs
-
Pacira Pharmaceuticals Inc. (PCRX) Tops Q2 EPS by 7c; Reaffirms Outlook
Back to PCRX Stock Lookup